Unknown

Dataset Information

0

Functional Classification of TP53 Mutations in Acute Myeloid Leukemia.


ABSTRACT: Mutations of the TP53 gene occur in a subset of patients with acute myeloid leukemia (AML) and confer an exceedingly adverse prognosis. However, whether different types of TP53 mutations exert a uniformly poor outcome has not been investigated yet. Here, we addressed this issue by analyzing data of 1537 patients intensively treated within protocols of the German-Austrian AML study group. We classified TP53 mutations depending on their impact on protein structure and according to the evolutionary action (EAp53) score and the relative fitness score (RFS). In 98/1537 (6.4%) patients, 108 TP53 mutations were detected. While the discrimination depending on the protein structure and the EAp53 score did not show a survival difference, patients with low-risk and high-risk AML-specific RFS showed a different overall survival (OS; median, 12.9 versus 5.5 months, p = 0.017) and event-free survival (EFS; median, 7.3 versus 5.2 months, p = 0.054). In multivariable analyses adjusting for age, gender, white blood cell count, cytogenetic risk, type of AML, and TP53 variant allele frequency, these differences were statistically significant for both OS (HR, 2.14; 95% CI, 1.15-4.0; p = 0.017) and EFS (HR, 1.97; 95% CI, 1.06-3.69; p = 0.033). We conclude that the AML-specific RFS is of prognostic value in patients with TP53-mutated AML and a useful tool for therapeutic decision-making.

SUBMITTER: Dutta S 

PROVIDER: S-EPMC7139772 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Functional Classification of <i>TP53</i> Mutations in Acute Myeloid Leukemia.

Dutta Sayantanee S   Pregartner Gudrun G   Rücker Frank G FG   Heitzer Ellen E   Zebisch Armin A   Bullinger Lars L   Berghold Andrea A   Döhner Konstanze K   Sill Heinz H  

Cancers 20200310 3


Mutations of the <i>TP53</i> gene occur in a subset of patients with acute myeloid leukemia (AML) and confer an exceedingly adverse prognosis. However, whether different types of <i>TP53</i> mutations exert a uniformly poor outcome has not been investigated yet. Here, we addressed this issue by analyzing data of 1537 patients intensively treated within protocols of the German-Austrian AML study group. We classified <i>TP53</i> mutations depending on their impact on protein structure and accordin  ...[more]

Similar Datasets

| S-EPMC7529302 | biostudies-literature
| S-EPMC7897660 | biostudies-literature
| S-EPMC6395341 | biostudies-literature
| S-EPMC3358364 | biostudies-literature
| S-EPMC5144553 | biostudies-literature
| S-EPMC5269552 | biostudies-literature
| S-EPMC4317506 | biostudies-literature
| S-EPMC10136154 | biostudies-literature
2022-03-08 | PXD022894 | Pride
2022-03-08 | PXD023090 | Pride